Compare GFF & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | PBLS |
|---|---|---|
| Founded | 1959 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 1994 | 2026 |
| Metric | GFF | PBLS |
|---|---|---|
| Price | $97.59 | $39.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $105.00 | N/A |
| AVG Volume (30 Days) | 265.5K | ★ 342.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $2,519,926,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.01 | $25.56 |
| 52 Week High | $108.57 | $41.49 |
| Indicator | GFF | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 61.91 |
| Support Level | $88.43 | $37.88 |
| Resistance Level | $108.57 | $41.49 |
| Average True Range (ATR) | 2.42 | 1.97 |
| MACD | -0.72 | -0.19 |
| Stochastic Oscillator | 32.82 | 54.70 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.